Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.48 |
| ▸ | CA1 | P00915 | 1/20 | 0.48 |
| ▸ | CA2 | P00918 | 1/20 | 0.48 |
| ▸ | CA7 | P43166 | 1/20 | 0.48 |
| ▸ | CA9 | Q16790 | 1/20 | 0.48 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 4/20 | 0.47 |
| ▸ | RAB9A | P51151 | 3/20 | 0.44 |
| ▸ | NPC1 | O15118 | 3/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | STAT3 | P40763 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.42 |
| ▸ | MAPT | P10636 | 3/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 3/20 | 0.42 |
| ▸ | HPGD | P15428 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20984492 | 0.88 | SMN1; SMN2 (0.50) | CA12CA1CA2CA7CA9 | |
| SCHEMBL20984476 | 0.88 | GAA (0.43) | CA12CA1CA2CA7CA9 | |
| SCHEMBL20984873 | 0.82 | ALDH1A1 (0.54) | GAARAB9AL3MBTL1POLBMAPT | |
| SCHEMBL18415530 | 0.79 | CA12 (0.52) | CA12CA1CA2CA7CA9 | |
| SCHEMBL20984472 | 0.78 | GAA (0.71) | GAAL3MBTL1POLBKDM4EMAPT | |
| SCHEMBL20984297 | 0.78 | GAA (0.54) | CA12CA1CA2CA7CA9 | |
| SCHEMBL20984757 | 0.77 | GAA (0.52) | CA12CA1CA2CA7CA9 | |
| SCHEMBL20984511 | 0.77 | GAA (0.52) | CA12CA1CA2CA7CA9 | |
| SCHEMBL20514178 | 0.77 | SMN1; SMN2 (0.57) | GAARAB9ANPC1POLBKDM4E | |
| SCHEMBL18415504 | 0.74 | CA12 (0.47) | CA12CA1CA2CA7CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107663161-B | Continuous flow synthesis process of phenylhydrazine salt and substituted phenylhydrazine salt | 上海惠和化德生物科技有限公司 | 2020-04-10 | — | — | CN | claimed |
| US-11040938-B2 | Continuous flow process for the synthesis of phenylhydrazine salts and substituted phenylhydrazine salts | SHANGHAI HYBRID-CHEM TECHNOLOGIES (CN) | 2021-06-22 | — | — | US | disclosed |
| CN-107663161-B | Continuous flow synthesis process of phenylhydrazine salt and substituted phenylhydrazine salt | 上海惠和化德生物科技有限公司 | 2020-04-10 | — | — | CN | disclosed |
| US-20190152896-A1 | Continuous Flow Process For the Synthesis of Phenylhydrazine Salts and Substituted Phenylhydrazine Salts | SHANGHAI HYBRID-CHEM TECHNOLOGIES (CN) | 2019-05-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11040938-B2 | Continuous flow process for the synthesis of phenylhydrazine salts and substituted phenylhydrazine salts | HPD, TYR, PDK2 | CA12 1659/4885CA1 1443/4885CA2 931/4885 |
| US-20190152896-A1 | Continuous Flow Process For the Synthesis of Phenylhydrazine Salts and Substituted Phenylhydrazine Salts | HPD, TYR, PDK2 | CA12 1659/4885CA1 1443/4885CA2 931/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.